Why Mark Cuban Invested in This Young Entrepreneur’s Biotech Business
And get this: The entrepreneur behind the business into which Cuban has poured his millions is just 22 years old.
Peeyush Shrivastava is his name. And he’s the co-founder of the biotech company Genetesis.
As CEO and co-founder of the company, Shrivastava helped create the firm’s flagship device, dubbed the “Faraday scanner” – a three-dimensional cardiac scanning machine – that could go to market nationwide as early as this year.
For individuals who suffer sudden bouts of chest pain, these machines will save them both time and money – not to mention their lives.
And for Cuban, this means Genetesis will cater to America’s largest population – the 73 million-member-strong baby boomer generation.
By 2031, the incidence of cardiovascular disease will be 65% to 75% of this population, or 40 to 45 million new potential patients, reported Diagnostic and Interventional Cardiology in 2015. And as the prevalence of heart problems soars for baby boomers, so does the number of incidents involving non-specific chest pain, which is the No. 1 reason for ER trips for individuals 45 and older, according to a June 2014 study published by the National Center for Biotechnology Information.
It’s clear why Cuban sees value here.
But for those of us who don’t have the millions – nay, billions – to invest in private biotech companies like Genetesis prior to their initial public offerings, getting in on the most lucrative opportunities before “the herd” catches wind of them feels virtually impossible.
That’s why we’ve done the hard work for you. In fact, we’ve found a company that not only takes advantage of America’s aging population, but is riding two other critical catalysts that will send its price sky high.
We see this firm jumping 62% in no time, and that’s being conservative.
The post Why Mark Cuban Invested in This Young Entrepreneur’s Biotech Business appeared first on Growth Stock Network.